Announcements Trials
Browse Landscape

Phase

Phase 1 17Phase 2 5Phase 1/2 4Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 7Thoracic 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1Dermatologic 1

Conditions

Keratosis, Actinic 46Melanoma 27Skin Neoplasms 14Carcinoma, Basal Cell 9Lymphoma, T-Cell, Cutaneous 8Neoplasm Metastasis 5Mycosis Fungoides 5Lung Neoplasms 5Keratosis 5Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma 3Breast Neoplasms 3Uveal Melanoma 2Skin Diseases 2Sezary Syndrome 2Prostatic Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Subcutaneous panniculitis-like T-cell lymphoma 1Squamous Cell Carcinoma of Head and Neck 1Skin Substitutes 1Seroma 1Renal Transplant Patients at High-risk for Skin Cancer 1Psoriasis 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Glioma × Dermatologic × Clear all
NCT03340506 2026-04-20

Dabrafenib and/or Trametinib Rollover Study

Novartis

Phase 4 Recruiting
100 enrolled
CNSDermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡